Abiopharma

🔍 Makode Gail D (Executive)

Company: OMEGA HEALTHCARE INVESTORS INC (OHI)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Sold 14,863 shares of Profits Interest Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 106,821.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 5,620 shares of Profits Interest Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 101,201.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Acquired 14,863 shares of OP Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 218,888.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2
• Acquired 5,620 shares of OP Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 224,508.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2

Footnotes:

• F1: Represents Profits Interest Units ("PIUs") in OHI Healthcare Properties Limited Partnership (the "Operating Partnership"), of which the Issuer is the general partner. Each PIU represents a contingent right to receive one unit of limited partnership interest (an "OP Unit") in the Operating Partnership upon vesting and the satisfaction of certain tax-driven economic requirements.
• F2: Each OP Unit is redeemable at the election of the holder for cash equal to the then fair market value of one share of Issuer common stock, or at the Issuer's election, one share of Issuer common stock, subject to adjustment as set forth in the partnership agreement. The OP Units have no expiration date.
• F3: Represents 25% of the PIUs that vested into OP Units at the end of each calendar quarter in 2026 based on the Absolute Total Shareholder Return for the 2023-2025 performance period, subject to continued employment and accelerated vesting under certain circumstances, as certified by the Compensation Committee on January 8, 2026.
• F4: Represents 25% of the PIUs that vested into OP Units at the end of each calendar quarter in 2026 based on the Relative Total Shareholder Return for the 2023-2025 performance period, subject to continued employment and accelerated vesting under certain circumstances, as certified by the Compensation Committee on January 8, 2026.